Sanofi SA
SNW
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Stocks News & Analysis
stocks
Two cheap wide moat ASX shares
These shares are trading at a discount to our fair value discount and have sustainable competitive advantages.
stocks
Anthropic: Are the shares undervalued given the IPO pricing range?
There may be meaningful upside as Anthropic is pricing its stock as a reflection of current sentiment, not the company’s fundamentals.
stocks
Valuation looks stretched for ASX healthcare share
Strong fundamentals meet a demanding valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,274.20 | 17.10 | -0.18% |
| CAC 40 | 8,342.51 | 9.64 | 0.12% |
| DAX 40 | 26,694.28 | 31.51 | 0.12% |
| Dow JONES (US) | 52,420.14 | 66.35 | -0.13% |
| FTSE 100 | 10,823.90 | 11.57 | -0.11% |
| HKSE | 24,008.55 | 307.37 | -1.26% |
| NASDAQ | 25,305.88 | 160.31 | -0.63% |
| Nikkei 225 | 60,819.36 | 429.23 | -0.70% |
| NZX 50 Index | 14,259.23 | 79.37 | 0.56% |
| S&P 500 | 7,587.90 | 31.48 | -0.41% |
| S&P/ASX 200 | 9,146.80 | 6.40 | -0.07% |
| SSE Composite Index | 3,655.83 | 24.81 | -0.67% |